Navigation Links
Amedica Names Distinguished Health Care Industry Executive Jay M. Moyes To Board Of Directors
Date:11/5/2012

SALT LAKE CITY, Nov. 5, 2012 /PRNewswire/ -- Amedica Corporation, a spinal and reconstructive medical device manufacturer, announced today that esteemed financial executive Jay M. Moyes has been elected to its Board of Directors.

Mr. Moyes brings more than 30 years of management and leadership experience to the Amedica Board of Directors.  He has been instrumental in the financial development and expansion of some of the medical industry's most groundbreaking companies including Myriad Genetics, where he guided the company through its initial public offering.  Mr. Moyes currently sits on the Board of Directors with multiple biotechnology companies including Osiris Therapeutics Inc., Biocardia Inc., Integrated Diagnostics Inc., and Puma Biotechnology Inc.  He formerly held a Board position with the Utah Life Science Industry Association.

"Jay brings a unique perspective to the Amedica leadership team.  His experience and insight are incredibly valued as we work to further establish Amedica's position in the orthopedic industry," said Eric K. Olson, President and Chief Executive Officer, Amedica.  "We look forward to drawing on the depth of his knowledge and business expertise as we expand our market penetration and continue developing innovative products that provide both clinical and economic value."

Throughout Mr. Moyes's career, he has worked with numerous industry-leading companies through their transformation from emerging growth to established, publicly-traded companies.  Most recently, he served as Chief Financial Officer at XDX, an emerging molecular diagnostics company.  Previously he served in the same role at Myriad Genetics, a publicly traded, leading biotechnology company focused on molecular diagnostics and therapeutic development.  Prior to Myriad, Mr. Moyes served as Chief Financial Officer of Genmark, an agricultural biotechnology company, and as a Senior Manager with the international public accounting firm of KPMG.  He holds a Masters in Business Administration from the University of Utah and received his undergraduate degree in economics from Weber State University.

About AMEDICA Corporation:

Amedica is an innovative spine and orthopaedic implant and device manufacturing and distribution company that provides advanced surgical applications including silicon nitride ceramic technologies. The company's platform technologies represent a new standard for implants and biologics based on superior performance, safety and efficacy.  Amedica is a privately held, private equity backed company founded in 1996 by internationally recognized orthopaedic surgeons and ceramicists. The company is ISO 13485 certified, its spine products are FDA cleared, CE marked, and sold in ten countries. Amedica Corporation is based in Salt Lake City, UT.

Media Contact
Stacey Holifield / Heather McIntyre
Schwartz MSL
(781) 684-0770
AMEDICA@schwartzmsl.com

 


'/>"/>
SOURCE Amedica Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
3. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
4. myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development
5. Bausch + Lomb Names John Barr Global President Surgical
6. Forbes Names Pharmalot, a UBM Canon Pharmaceutical Media Group Brand, as a Top Social Media Influencer
7. Wake Forest Baptist Names President of Piedmont Triad Research Park and Chief Innovation Officer
8. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
9. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
10. MedVantx Names New VP Employer Solutions and Workplace Health
11. Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , April 24, 2017 Solentim, the ... announced the addition of a major new product ... Plate Seeding,). The VIPS has been developed for ... well microplates as part of the process to ... a simple and more reliable solution when compared ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... have severe consequences to overall dental health, including complications with speech, eating, and overcompensation ... dental implants to replace lost teeth. As the number of tooth replacements increase, it ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Hackensack, N.J. has been honored by Enterprising Women magazine as one of its ... world’s top women business owners. Winners have demonstrated that they have fast-growth businesses, ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):